vs
Side-by-side financial comparison of ACADIA PHARMACEUTICALS INC (ACAD) and Root, Inc. (ROOT). Click either name above to swap in a different company.
Root, Inc. is the larger business by last-quarter revenue ($397.0M vs $284.0M, roughly 1.4× ACADIA PHARMACEUTICALS INC). On growth, Root, Inc. posted the faster year-over-year revenue change (21.5% vs 9.4%). Over the past eight quarters, Root, Inc.'s revenue compounded faster (24.8% CAGR vs 17.5%).
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, San Diego, California.
Root Insurance Company is an online car insurance company operating in the United States.
ACAD vs ROOT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | ||
|---|---|---|
| Revenue | $284.0M | $397.0M |
| Net Profit | $273.6M | — |
| Gross Margin | 90.8% | — |
| Operating Margin | 6.1% | 2.6% |
| Net Margin | 96.3% | — |
| Revenue YoY | 9.4% | 21.5% |
| Net Profit YoY | 90.3% | — |
| EPS (diluted) | $1.61 | $0.35 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $284.0M | $397.0M | ||
| Q3 25 | $278.6M | $387.8M | ||
| Q2 25 | $264.6M | $382.9M | ||
| Q1 25 | $244.3M | $349.4M | ||
| Q4 24 | $259.6M | $326.7M | ||
| Q3 24 | $250.4M | $305.7M | ||
| Q2 24 | $242.0M | $289.2M | ||
| Q1 24 | $205.8M | $254.9M |
| Q4 25 | $273.6M | — | ||
| Q3 25 | $71.8M | $-5.4M | ||
| Q2 25 | $26.7M | $22.0M | ||
| Q1 25 | $19.0M | $18.4M | ||
| Q4 24 | $143.7M | — | ||
| Q3 24 | $32.8M | $22.8M | ||
| Q2 24 | $33.4M | $-7.8M | ||
| Q1 24 | $16.6M | $-6.2M |
| Q4 25 | 90.8% | — | ||
| Q3 25 | 92.2% | — | ||
| Q2 25 | 92.2% | — | ||
| Q1 25 | 91.7% | — | ||
| Q4 24 | 91.6% | — | ||
| Q3 24 | 92.5% | — | ||
| Q2 24 | 92.5% | — | ||
| Q1 24 | 88.8% | — |
| Q4 25 | 6.1% | 2.6% | ||
| Q3 25 | 12.8% | 0.1% | ||
| Q2 25 | 12.2% | 7.1% | ||
| Q1 25 | 7.9% | 6.8% | ||
| Q4 24 | 59.1% | 10.7% | ||
| Q3 24 | 12.6% | 11.3% | ||
| Q2 24 | 12.6% | 1.3% | ||
| Q1 24 | 7.4% | 2.1% |
| Q4 25 | 96.3% | — | ||
| Q3 25 | 25.8% | -1.4% | ||
| Q2 25 | 10.1% | 5.7% | ||
| Q1 25 | 7.8% | 5.3% | ||
| Q4 24 | 55.4% | — | ||
| Q3 24 | 13.1% | 7.5% | ||
| Q2 24 | 13.8% | -2.7% | ||
| Q1 24 | 8.0% | -2.4% |
| Q4 25 | $1.61 | $0.35 | ||
| Q3 25 | $0.42 | $-0.35 | ||
| Q2 25 | $0.16 | $1.29 | ||
| Q1 25 | $0.11 | $1.07 | ||
| Q4 24 | $0.86 | $1.42 | ||
| Q3 24 | $0.20 | $1.35 | ||
| Q2 24 | $0.20 | $-0.52 | ||
| Q1 24 | $0.10 | $-0.42 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | ||
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $177.7M | $669.3M |
| Total DebtLower is stronger | — | $200.3M |
| Stockholders' EquityBook value | $1.2B | $284.3M |
| Total Assets | $1.6B | $1.7B |
| Debt / EquityLower = less leverage | — | 0.70× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $177.7M | $669.3M | ||
| Q3 25 | $258.0M | $653.3M | ||
| Q2 25 | $253.6M | $641.4M | ||
| Q1 25 | $217.7M | $609.4M | ||
| Q4 24 | $319.6M | $599.3M | ||
| Q3 24 | $155.1M | $674.8M | ||
| Q2 24 | $177.1M | $667.2M | ||
| Q1 24 | $204.7M | $640.5M |
| Q4 25 | — | $200.3M | ||
| Q3 25 | — | $200.4M | ||
| Q2 25 | — | $200.1M | ||
| Q1 25 | — | $200.0M | ||
| Q4 24 | — | $200.1M | ||
| Q3 24 | — | $300.9M | ||
| Q2 24 | — | $300.1M | ||
| Q1 24 | — | $299.3M |
| Q4 25 | $1.2B | $284.3M | ||
| Q3 25 | $917.3M | $265.0M | ||
| Q2 25 | $822.4M | $244.5M | ||
| Q1 25 | $765.2M | $228.7M | ||
| Q4 24 | $732.8M | $203.7M | ||
| Q3 24 | $577.2M | $181.9M | ||
| Q2 24 | $516.7M | $151.3M | ||
| Q1 24 | $464.0M | $165.7M |
| Q4 25 | $1.6B | $1.7B | ||
| Q3 25 | $1.3B | $1.6B | ||
| Q2 25 | $1.2B | $1.6B | ||
| Q1 25 | $1.1B | $1.6B | ||
| Q4 24 | $1.2B | $1.5B | ||
| Q3 24 | $976.9M | $1.6B | ||
| Q2 24 | $914.1M | $1.5B | ||
| Q1 24 | $855.1M | $1.4B |
| Q4 25 | — | 0.70× | ||
| Q3 25 | — | 0.76× | ||
| Q2 25 | — | 0.82× | ||
| Q1 25 | — | 0.87× | ||
| Q4 24 | — | 0.98× | ||
| Q3 24 | — | 1.65× | ||
| Q2 24 | — | 1.98× | ||
| Q1 24 | — | 1.81× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | ||
|---|---|---|
| Operating Cash FlowLast quarter | $-48.7M | $206.5M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | -0.18× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-48.7M | $206.5M | ||
| Q3 25 | $74.3M | $57.6M | ||
| Q2 25 | $64.0M | $52.0M | ||
| Q1 25 | $20.3M | $26.8M | ||
| Q4 24 | $40.4M | $195.7M | ||
| Q3 24 | $63.2M | $49.4M | ||
| Q2 24 | $25.0M | $62.6M | ||
| Q1 24 | $29.1M | $14.5M |
| Q4 25 | — | — | ||
| Q3 25 | $73.9M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $195.3M | ||
| Q3 24 | $63.2M | — | ||
| Q2 24 | — | $62.4M | ||
| Q1 24 | — | $14.3M |
| Q4 25 | — | — | ||
| Q3 25 | 26.5% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 59.8% | ||
| Q3 24 | 25.2% | — | ||
| Q2 24 | — | 21.6% | ||
| Q1 24 | — | 5.6% |
| Q4 25 | — | 0.0% | ||
| Q3 25 | 0.1% | 0.0% | ||
| Q2 25 | — | 0.0% | ||
| Q1 25 | — | 0.0% | ||
| Q4 24 | — | 0.1% | ||
| Q3 24 | 0.0% | 0.0% | ||
| Q2 24 | — | 0.1% | ||
| Q1 24 | — | 0.1% |
| Q4 25 | -0.18× | — | ||
| Q3 25 | 1.03× | — | ||
| Q2 25 | 2.40× | 2.36× | ||
| Q1 25 | 1.07× | 1.46× | ||
| Q4 24 | 0.28× | — | ||
| Q3 24 | 1.93× | 2.17× | ||
| Q2 24 | 0.75× | — | ||
| Q1 24 | 1.76× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACAD
| Nuplazid | $174.4M | 61% |
| Daybue | $109.6M | 39% |
ROOT
Segment breakdown not available.